Trial Profile

A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEP-UP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Sep 2025 Planned End Date changed from 17 May 2025 to 30 Oct 2025.
04 Jun 2024 Results evaluating cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma receiving step-up priming doses and longer dosing intervals of elranatamab, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
29 Apr 2024 According to Pfizer media release, data from this trial will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com